Treatment of Parkinson's Disease with Impulse Control Disorder in Patients on Dopamine Agonists

Clinical Scenario

This protocol addresses a specific and clinically significant complication: the development of impulse control disorder (ICD) in patients with Parkinson's disease who are receiving dopamine agonist therapy.

Key Comorbidity

Impulse control disorders are a recognised complication associated with dopamine agonist use in Parkinson's disease. Managing this comorbidity requires careful adjustment of the current treatment regimen while addressing the behavioural symptoms directly.

Approach Overview

The structured regimen for this scenario involves adjustments to dopamine agonist therapy combined with a specific behavioural intervention. The approach accounts for the risk of a withdrawal syndrome when modifying dopamine agonist treatment.

The complete regimen — including sequencing, conditions for each step, and all clinical decision points — is available via the full protocol below.